vedolizumab
Sign in to saveAlso known as LDP-02, MLN-02, MLN-0002
Vedolizumab, sold under the brand name Entyvio, is a monoclonal antibody medication developed by Takeda Oncology for the treatment of ulcerative colitis and Crohn's disease. It binds to integrin α4β7 (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1, a dimer of Integrin alpha-4 and Integrin beta-7), blocking the α4β7 integrin results in gut-selective anti-inflammatory activity.
Key facts
- Drug.S
- 42
- Drug.O
- 2042
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 470629476
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- zu
- Drug.target
- Integrin α4β7
- Drug.tradename
- Entyvio
- Drug.MedlinePlus
- a614034
- Drug.DailyMedID
- Vedolizumab
- Drug.pregnancy_AU
- B2
- Drug.routes_of_administration
- Intravenous
- Drug.ATC_prefix
- L04
- Drug.ATC_suffix
- AG05
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
via Wikipedia infobox
Research
2,794 papers- Vedolizumab as induction and maintenance therapy for ulcerative colitis.The New England journal of medicine · 2013
- Long-term safety of vedolizumab for inflammatory bowel disease.Alimentary pharmacology & therapeutics · 2020
- Vedolizumab as induction and maintenance therapy for Crohn's disease.The New England journal of medicine · 2013
- Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis.Gastroenterology · 2020
- An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab.Journal of Crohn's & colitis · 2016
via PubMed
~8 min read
Encyclopedic overview
11 sectionsContents
- Medical use
- Ulcerative colitis and Crohn's disease
- Checkpoint inhibitor colitis
- Clinical trials
- Ulcerative colitis
- Crohn's disease
- History
- Society and culture
- Legal status
- Research
- References
Vedolizumab, sold under the brand name Entyvio, is a monoclonal antibody medication developed by Takeda Oncology for the treatment of ulcerative colitis and Crohn's disease. It binds to integrin α4β7 (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1, a dimer of Integrin alpha-4 and Integrin beta-7), blocking the α4β7 integrin results in gut-selective anti-inflammatory activity.
== Medical use ==
Excerpted from Wikipedia’s “vedolizumab” article, available under the CC BY-SA 4.0 licence.